Diabetes and COVID-19: The past, the present, and the future

Pranata, Raymond; Henrina, Joshua; Raffaello, Wilson Matthew; Lawrensia, Sherly; Huang, Ian

doi:10.1016/j.metabol.2021.154814

Cited by 70 publications

(61 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were 6 (60%) male patients and 4 female patients: a male/female ratio of 1.5 to 1. The mean HbA1c was 7.52% ( Anker et al, 2011 ; Charpentier et al, 2011 ; Shane-McWhorter et al, 2014 ; Lindberg et al, 2017 ; Zulfiqar et al, 2020a ; Pranata et al, 2021 ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Glycemic Disorder Risk Remote Monitoring Program in the COVID-19 Very Elderly Patients: Preliminary Results

Zulfiqar

Massimbo²,

Hajjam³

et al. 2021

Front. Physiol.

View full text Add to dashboard Cite

Introduction: The coronavirus disease 2019 (COVID-19) pandemic has necessitated the use of new technologies and new processes to care for hospitalized patients, including diabetes patients. This was the basis for the “GER-e-TEC COVID study,” an experiment involving the use of the smart MyPrediTM e-platform to automatically detect the exacerbation of glycemic disorder risk in COVID-19 older diabetic patients.Methods: The MyPrediTM platform is connected to a medical analysis system that receives physiological data from medical sensors in real time and analyzes this data to generate (when necessary) alerts. An experiment was conducted between December 14th, 2020 and February 25th, 2021 to test this alert system. During this time, the platform was used on COVID-19 patients being monitored in an internal medicine COVID-19 unit at the University Hospital of Strasbourg. The alerts were compiled and analyzed in terms of sensitivity, specificity, positive and negative predictive values with respect to clinical data.Results: 10 older diabetic COVID-19 patients in total were monitored remotely, six of whom were male. The mean age of the patients was 84.1 years. The patients used the telemedicine solution for an average of 14.5 days. 142 alerts were emitted for the glycemic disorder risk indicating hyperglycemia, with an average of 20.3 alerts per patient and a standard deviation of 26.6. In our study, we did not note any hypoglycemia, so the system emitted any alerts. For the sensitivity of alerts emitted, the results were extremely satisfactory, and also in terms of positive and negative predictive values. In terms of survival analysis, the number of alerts and gender played no role in the length of the hospital stay, regardless of the reason for the hospitalization (COVID-19 management).Conclusion: This work is a pilot study with preliminary results. To date, relatively few projects and trials in diabetic patients have been run within the “telemedicine 2.0” setting, particularly using AI, ICT and the Web 2.0 in the era of COVID-19 disease.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Diabetes is strongly associated with a poor prognosis in COVID-19. Scrupulous blood sugar management is crucial, since the worse outcomes are closely associated with higher blood sugar levels in COVID-19 infection ( Pranata et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Glycemic Disorder Risk Remote Monitoring Program in the COVID-19 Very Elderly Patients: Preliminary Results

Zulfiqar

Massimbo²,

Hajjam³

et al. 2021

Front. Physiol.

View full text Add to dashboard Cite

show abstract

“…As COVID-19 pandemic is still underway, currently only fungal Mucormycosis and Aspergillosis infections have so far been reported affecting patients infected and recovering from COVID-19 ( Soman and Sunavala, 2021 , Manchanda et al, 2021 ). These patients have become immunocompromised due to different factors including the disease itself; exacerbation of existing chronic conditions such as diabetes mellitus during COVID-19 infection; and by using steroids and monoclonal antibody for treatment of COVID-19 ( Pranata et al, 2021 ). COVID-19 infection is associated with development and exacerbation of diabetes mellitus as part of COVID-19 disease and post-COVID-19 syndrome ( Pranata et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Fonsecaea associated cerebral phaeohyphomycosis in a post-COVID-19 patient: A first case report

Laiq

Yaqoobi

Saadi

et al. 2022

Clinical Infection in Practice

View full text Add to dashboard Cite

Phaeohyphomycosis, previously known as chromoblastomycosis, is a chronic mycosis, usually affecting the skin. It is caused by dematiaceous fungi, which are a group of fungi that produce melanin in their cell walls. Cerebral phaeohyphomycosis occurs as a part of invasive presentation of the fungi, which usually affects immunocompromised patients, but may affect immunocompetent individuals as well. Cerebral infection in phaeohyphomycosis is associated with a poor prognosis regardless of the immune status of the patient. COVID-19 SARS-CoV-2 infection and/or medications used for its treatment may compromise the immune system, including in the post-COVID-19 period, resulting in invasive fungal infections, which have frequently been reported recently during the COVID-19 pandemic. We report a case of Fonsecaea associated cerebral phaeohyphomycosis in a recently diagnosed diabetic Omani lady, who presented to our hospital 6 weeks after recovery and discharge from hospitalization for moderate COVID-19 pneumonia.

show abstract

“…Interestingly, diabetes does not significantly affect ivermectin's benefit. Some antidiabetic drugs have been shown to lower mortality in COVID-19 and glucose control seemed to be an important component in these patients [ [31] , [32] , [33] , [34] ]. These factors were vaguely reported by the included studies and may affect the analysis.…”

Section: Discussionmentioning

confidence: 99%

Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials

Zein

Sulistiyana

Raffaello

et al. 2021

Diabetes & Metabolic Syndrome: Clinical Research & Revi

Self Cite

View full text Add to dashboard Cite

Aims This systematic review and meta-analysis aims to investigate the effect of ivermectin on mortality in patients with COVID-19. Methods A comprehensive systematic literature search was performed using PubMed, Scopus, Embase, and Clinicaltrials.gov from the inception of databases up until 9 April 2021. The intervention group was ivermectin and the control group was standard of care or placebo. The primary outcome was mortality reported as risk ratio (RR). Results There were 9 RCTs comprising of 1788 patients included in this meta-analysis. Ivermectin was associated with decreased mortality (RR 0.39 [95% 0.20–0.74], p = 0.004; I 2 : 58.2%, p = 0.051). Subgroup analysis in patients with severe COVID-19 showed borderline statistical significance towards mortality reduction (RR 0.42 [95% 0.18–1.00], p = 0.052; I 2 : 68.3, p = 0.013). The benefit of ivermectin and mortality was reduced by hypertension (RR 1.08 [95% CI 1.03–1.13], p = 0.001); but was not influenced by age (p = 0.657), sex (p = 0.466), diabetes (p = 0.429). Sensitivity analysis using fixed-effect model showed that ivermectin decreased mortality in general (RR 0.43 [95% CI 0.29–0.62], p < 0.001) and severe COVID-19 subgroup (RR 0.48 [95% CI 0.32–0.72], p < 0.001). Conclusions Ivermectin was associated with decreased mortality in COVID-19 with a low certainty of evidence. Further adequately powered double-blinded placebo-controlled RCTs are required for definite conclusion.

show abstract

Diabetes and COVID-19: The past, the present, and the future

Cited by 70 publications

References 113 publications

Glycemic Disorder Risk Remote Monitoring Program in the COVID-19 Very Elderly Patients: Preliminary Results

Glycemic Disorder Risk Remote Monitoring Program in the COVID-19 Very Elderly Patients: Preliminary Results

Fonsecaea associated cerebral phaeohyphomycosis in a post-COVID-19 patient: A first case report

Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials

Contact Info

Product

Resources

About